Relay Therapeutics, Inc.
RLAY
Classificação em ações
#4265
Relay Therapeutics, Inc. is a precision medicine company currently engaged in... Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Preço da ação
$16.79
Valor de mercado
$3.68B
Variação (1 dia)
3.13%
Variação (1 ano)
158.71%
País
US
Negociar Relay Therapeutics, Inc. (RLAY)
Categoria
Healthcare
Margem Operacional de Relay Therapeutics, Inc. (RLAY)
Margem Operacional em October 2026 TTM: -2,999.38%
De acordo com os relatórios financeiros mais recentes e o preço das ações da Relay Therapeutics, Inc., a margem operacional atual (TTM) é -2,999.38%. No final de 2023, a margem operacional era -1,460.11%.
Histórico da Margem Operacional da Relay Therapeutics, Inc. de 2018 a 2026
Margem Operacional no final de cada ano
| Ano | Margem Operacional | Alterar |
|---|---|---|
| 2026 (TTM) | -2,999.38% | -19.42% |
| 2024 | -3,722.07% | 154.92% |
| 2023 | -1,460.11% | -93.26% |
| 2022 | -21,670.89% | 79.99% |
| 2021 | -12,040.21% | 17,734.71% |
| 2020 | -67.51% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
Margem Operacional de empresas semelhantes ou concorrentes
| Empresa | Margem Operacional | Diferença na Margem Operacional | País |
|---|---|---|---|
| 38.59% | -100.01% |
US
|
|
| -149.01% | -99.95% |
US
|
|
| 25.57% | -100.01% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.01% |
NL
|
O que é a Margem Operacional de uma empresa?
A Margem Operacional é um indicador essencial para avaliar a rentabilidade de uma empresa. Margens operacionais mais altas geralmente são melhores, pois mostram que uma empresa consegue vender seus produtos ou serviços por muito mais do que o custo de produzi-los. É calculada dividindo os lucros da empresa pela sua receita.